NCT05152277

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered HRS9531

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous injections of HRS9531 in healthy subjects.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	HRS9531	Administered SC once
OTHER	placebo	Administered SC once
DRUG	HRS9531	Administered SC for multiple dose
OTHER	placebo	Administered SC for multiple dose

Timeline

• Start date: 2021-12-06
• Primary completion: 2022-08-24
• Completion: 2022-08-24
• First posted: 2021-12-09
• Last updated: 2022-09-19

Locations

1 site across 1 country: China